

## Notice under ASX Listing Rule 3.10A

Nexsen Limited (ASX:NXN) ("**Nexsen**" or the "**Company**") provides the following notice under ASX Listing Rule 3.10A in relation to the upcoming release of securities from escrow.

The following Fully Paid Ordinary Shares ("**Shares**") are due to be released in the next month:

| Number and Class  | ASX Code | Release Date     |
|-------------------|----------|------------------|
| 6,000,000 Shares  | NXNAA    | 5 February 2026  |
| 14,200,000 Shares | NXNAB    | 24 February 2026 |

NXNAA is held by RMIT University, the key research partner to Nexsen across its suite of rapid point-of-care diagnostics development. NXNAB is held by various pre-IPO investors in the Company.

These Shares are presently unquoted (as they are ASX restricted securities). The Company will seek quotation of these Shares following their release from escrow. These Shares are on the same terms and rank equally with all other Shares on issue.

-ENDS-

ASX release authorised by the Managing Director.

For more information, please contact:

### Corporate Enquiries

Nexsen Limited

e: [corporate@nexsen.bio](mailto:corporate@nexsen.bio)

w: [nexsen.bio](https://nexsen.bio)

Reign Advisory

e: [NXN@reignadvisory.com](mailto:NXN@reignadvisory.com)

p: + 61 2 9174 5388

### Media Enquiries

Jane Morgan Management

e: [info@janemorganmanagement.com.au](mailto:info@janemorganmanagement.com.au)

Join our Investor Centre

SCAN ME



### About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics that deliver lab-grade results for conditions that have traditionally relied on delayed lab testing. The company focuses on areas of significant unmet clinical need, where faster answers can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The company is also developing rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.